Published in Biochem Biophys Res Commun on August 05, 1996
Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. Mol Imaging (2009) 0.90
A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation. Anal Biochem (2007) 0.77
Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem (2000) 2.35
Implementation of semi-automated cloning and prokaryotic expression screening: the impact of SPINE. Acta Crystallogr D Biol Crystallogr (2006) 1.56
Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol (2002) 1.49
Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target (1998) 1.46
The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci (1997) 1.44
Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci (1998) 1.19
The three-dimensional structure of thymidine kinase from herpes simplex virus type 1. FEBS Lett (1995) 1.16
Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab (2003) 1.13
Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Nat Biotechnol (1999) 1.13
Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes. Biochemistry (1994) 1.13
Application of high-throughput technologies to a structural proteomics-type analysis of Bacillus anthracis. Acta Crystallogr D Biol Crystallogr (2006) 1.11
A fast and inexpensive method for N-terminal fluorescein-labeling of peptides. Bioorg Med Chem Lett (1998) 1.07
Substrate diversity of herpes simplex virus thymidine kinase. Impact Of the kinematics of the enzyme. J Biol Chem (1999) 1.03
Molecular cloning, genetic mapping, and developmental expression of bovine POU5F1. Biol Reprod (1999) 1.02
A cyclic AMP response element is involved in retinoic acid-dependent RAR beta 2 promoter activation. Nucleic Acids Res (1992) 1.01
A spectrophotometric assay for quantitative determination of kcat of herpes simplex virus type 1 thymidine kinase substrates. Anal Biochem (2001) 0.96
The solution structure of the lantibiotic gallidermin. Biopolymers (1991) 0.96
Drug resistance of herpes simplex virus type 1--structural considerations at the molecular level of the thymidine kinase. Eur J Biochem (1998) 0.95
An analysis of the helix-to-strand transition between peptides with identical sequence. Proteins (2000) 0.94
Molecular dynamics study of a complex between the human histocompatibility antigen HLA-A2 and the IMP58-66 nonapeptide from influenza virus matrix protein. Eur J Biochem (1992) 0.92
Relevance relations for the concept of reproducibility. J R Soc Interface (2014) 0.90
A fast method for obtaining highly pure recombinant herpes simplex virus type 1 thymidine kinase. Protein Expr Purif (1994) 0.90
Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Pharm Acta Helv (1996) 0.90
Molecular dynamics of the alpha-helical epitope of a novel synthetic lipopeptide foot-and-mouth disease virus vaccine. Biopolymers (1989) 0.88
Nucleoside binding site of herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography. Proteins (2000) 0.87
Use of fluorescence polarization to monitor MHC-peptide interactions in solution. J Immunol Methods (2001) 0.87
Millisecond to microsecond time scale dynamics of the retinoid X and retinoic acid receptor DNA-binding domains and dimeric complex formation. Biochemistry (1999) 0.85
Folding and self-assembly of herpes simplex virus type 1 thymidine kinase. J Mol Biol (2001) 0.85
Beta-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope. J Biol Chem (2001) 0.85
Nucleotide-binding properties of adenylate kinase from Escherichia coli: a molecular dynamics study in aqueous and vacuum environments. J Comput Aided Mol Des (1994) 0.85
Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine. Biochemistry (2000) 0.85
Density functional studies on herpes simplex virus type 1 thymidine kinase-substrate interactions: the role of Tyr-172 and Met-128 in thymine fixation. Proteins (1998) 0.85
Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline. Clin Exp Immunol (1993) 0.85
Increased risk of cervical abnormalities among HIV-infected African women. NIAID AIDS Agenda (1996) 0.85
Molecular modeling of an antigenic complex between a viral peptide and a class I major histocompatibility glycoprotein. Proteins (1992) 0.84
On the role of thymopoietins in cell proliferation. Immunochemical evidence for new members of the human thymopoietin family. Biol Chem (1999) 0.82
A new pharmophoric model for 5-HT reuptake-inhibitors: differentiation of amphetamine analogues. Pharm Acta Helv (1994) 0.82
Compulsory order of substrate binding to herpes simplex virus type 1 thymidine kinase. A calorimetric study. J Biol Chem (2000) 0.81
The rational of catalytic activity of herpes simplex virus thymidine kinase. a combined biochemical and quantum chemical study. J Biol Chem (2001) 0.81
Unusual stereospecificity of the potential antidepressant rolipram on the cyclic AMP generating system from rat brain cortex. Pharmacopsychiatry (1988) 0.80
Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc Natl Acad Sci U S A (1995) 0.80
Thermodynamic stability of HLA-B*2705. Peptide complexes. Effect of peptide and major histocompatibility complex protein mutations. J Biol Chem (2000) 0.79
Immune system activation boosts HIV replication in HIV-infected people. NIAID AIDS Agenda (1996) 0.79
Cytotoxic and antibacterial dihydrochalcones from Piper aduncum. J Nat Prod (1994) 0.79
Fine specificity of antigen binding to two class I major histocompatibility proteins (B*2705 and B*2703) differing in a single amino acid residue. J Comput Aided Mol Des (1997) 0.78
Understanding the selectivity of fumagillin for the methionine aminopeptidase type II. Oncol Res (2003) 0.78
Two new protease inhibitors approved by FDA. Food and Drug Administration. NIAID AIDS Agenda (1996) 0.78
Three-dimensional model of the cyclin-dependent kinase 1 (CDK1): Ab initio active site parameters for molecular dynamics studies of CDKS. Proteins (2001) 0.78
Structure-activity relationships of cannabinoids: a joint CoMFA and pseudoreceptor modelling study. J Comput Aided Mol Des (1997) 0.77
Highly purified recombinant varicella Zoster virus thymidine kinase is a homodimer. Protein Expr Purif (2000) 0.77
The effect of substrate binding on the conformation and structural stability of Herpes simplex virus type 1 thymidine kinase. Protein Sci (2001) 0.77
Site-directed mutagenesis in the active site of the herpes simplex virus type 1 thymidine kinase gene. Virus Genes (1993) 0.77
Mutation of Cys-67 alters the thermodynamic stability of the human leukocyte antigen HLA0-B*2705. J Biol Chem (2001) 0.77
Nonapeptide analogues containing (R)-3-hydroxybutanoate and beta-homoalanine oligomers: synthesis and binding affinity to a class I major histocompatibility complex protein. J Med Chem (1999) 0.77
Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci (1998) 0.77
Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705. J Pept Sci (1998) 0.77
Interaction of the recombinant herpes simplex virus type 1 thymidine kinase with thymidine and aciclovir: a kinetic study. Nucleosides Nucleotides (1999) 0.77
A new approach to secondary structure evaluation: secondary structure prediction of porcine adenylate kinase and yeast guanylate kinase by CD spectroscopy of overlapping synthetic peptide segments. Biopolymers (1997) 0.77
[Feasibility of isolating and purifying thymidine kinases with the use of affinity chromatography]. Pharm Unserer Zeit (1989) 0.77
[Localization of the essential structure for binding of antiviral agents to thymidine kinase by studying sequence homologies]. Arch Pharm (Weinheim) (1989) 0.77
Conformational and epitope mapping of herpes-simplex-virus type-1 thymidine kinase using synthetic peptide segments. Eur J Biochem (1991) 0.76
[The development of pharmacophore models for thymidine kinase-dependent virostatic nucleoside analogs]. Arch Pharm (Weinheim) (1989) 0.76
Molecular dynamics and structure-based drug design for predicting non-natural nonapeptide binding to a class I MHC protein. Acta Crystallogr D Biol Crystallogr (1995) 0.76
A rationally designed oligopeptide shows significant conformational changes upon binding to sulphate ions. Biosens Bioelectron (2001) 0.76
Substituting nonpeptidic spacers for the T cell receptor-binding part of class I major histocompatibility complex-binding peptides. J Biol Chem (1998) 0.76
Putative KS virus grown in laboratory. NIAID AIDS Agenda (1996) 0.75
NIAID funds adult AIDS clinical trials group. National Institute of Allergy and Infectious Diseases. NIAID AIDS Agenda (1995) 0.75
NIAID pursues studies of gene therapy for HIV infection. National Institute of Allergy and Infectious Diseases. NIAID AIDS Agenda (1995) 0.75
[The synthesis of potential 5-lipoxygenase inhibitors. 1]. Arch Pharm (Weinheim) (1986) 0.75
A transferred NOE study of a tricyclic analog of acyclovir bound to thymidine kinase. J Biomol NMR (1996) 0.75
A pseudoreceptor modelling study of the varicella-zoster virus and human thymidine kinase binding sites. J Comput Aided Mol Des (1995) 0.75
SPIRAT group begins clinical trial of DNA-based therapeutic vaccine. Strategic Program for Innovative Research on AIDS Treatment. NIAID AIDS Agenda (1995) 0.75
Fauci presents new findings on HIV escape mechanisms and HIV suppressor molecules. NIAID AIDS Agenda (1996) 0.75
Cell fingerprinting: an approach to classifying cells according to mass profiles of digests of protein extracts. Proteomics (2001) 0.75
Vaccines and their transfection potency. Vaccine (1999) 0.75
Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action. Pharm Acta Helv (1999) 0.75
NIAID mounts nationwide HIV-TB treatment study. Public Health Rep (1993) 0.75
HIV persists and can replicate despite prolonged combination therapy. NIAID AIDS Agenda (1997) 0.75
A pseudo-particle approach for studying protein-ligand models truncated to their active sites. Biopolymers (1996) 0.75
[Adenosine receptor ligands--drugs of the future?]. Pharm Unserer Zeit (1989) 0.75
A delicate balance: levels of HIV replication are strongly influenced by interaction of positive and negative host factors. NIAID AIDS Agenda (1996) 0.75
Gene technology-based antimetabolite design: the use of an in vitro protein expression system to facilitate antimetabolite design for virally-induced human diseases and malignant conditions. Biotechnol Adv (1994) 0.75
NIAID studies of interleukin-2. National Institute of Allergy and Infectious Diseases. NIAID AIDS Agenda (1995) 0.75
Evaluation of the secondary structure of vaccinia-virus thymidine kinase by circular-dichroism spectroscopy of overlapping synthetic peptides. Eur J Biochem (1996) 0.75
Fauci presents NIAID strategy for HIV vaccine development. National Institute of Allergy and Infectious Diseases. NIAID AIDS Agenda (1996) 0.75
Fauci: new findings help explain HIV "rebound". NIAID AIDS Agenda (1998) 0.75
Secondary structure prediction of adenylate kinase by circular dichroism spectroscopy of synthetic peptides. Pharm Acta Helv (1995) 0.75
[The formation of potential toxic by-products in the in vitro decomposition of alpha-aminoalcohols]. Arch Pharm (Weinheim) (1985) 0.75
ADAPTU: animated dynamics analysis program at Tübingen University. J Mol Graph (1991) 0.75
CD4+ T cell diversity not immediately restored by therapy. NIAID AIDS Agenda (1997) 0.75
Gene therapy prolongs CD4+ T cell survival in HIV-infected individuals. NIAID AIDS Agenda (1996) 0.75
NMR-restrained docking of a peptidic inhibitor to the N-terminal domain of the phosphoenolpyruvate:sugar phosphotransferase enzyme I. J Comput Aided Mol Des (2001) 0.75
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases. NIAID AIDS Agenda (1997) 0.75
Oligonucleotide-directed mutagenesis and subsequent expression of the corresponding recombinant proteins without changing the bacterial vector system. Pharm Acta Helv (1997) 0.75
Peptides related to the active fragment of "proline rich polypeptide", an immunoregulatory protein of the ovine colostrum. Spectroscopic and computer modeling studies. Int J Pept Protein Res (1990) 0.75
Antiretrovirals plus immunomodulators: didanosine/interferon-alpha combination shows promise. NIAID AIDS Agenda (1996) 0.75
NIAID researchers identify cofactors for entry of HIV into cells. National Institute of Allergy and Infectious Diseases. NIAID AIDS Agenda (1996) 0.75
[Biological frost prevention in fish, frogs, flies and pines]. Pharm Unserer Zeit (1993) 0.75
ACTG 175: new insights into treating patients with intermediate-stage HIV disease. NIAID AIDS Agenda (1995) 0.75
[Synthesis of computer graphic calculated high-anti-fixed pyrimidine nucleoside analogs with potential virostatic and antineoplastic action]. Arch Pharm (Weinheim) (1989) 0.75